

# Markus Dietlein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7656376/publications.pdf>

Version: 2024-02-01

42  
papers

2,316  
citations

279798

23  
h-index

254184

43  
g-index

49  
all docs

49  
docs citations

49  
times ranked

2177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of [ <sup>18</sup> F]DCFPyL and [ <sup>68</sup> Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2015, 17, 575-584.	2.6	288
2	Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1547-1552.	6.4	276
3	EANM procedure guidelines for therapy of benign thyroid disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2218-2228.	6.4	174
4	Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1342-1348.	6.4	167
5	Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	1.6	151
6	PSA-Stratified Performance of <sup>18</sup> F- and <sup>68</sup> Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 947-952.	5.0	150
7	Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1671-1676.	2.1	146
8	Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1598-1609.	6.4	119
9	Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1441-1456.	2.1	62
10	Intraindividual Comparison of <sup>18</sup> F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 729-734.	5.0	58
11	Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 249-258.	6.4	49
12	Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 905-96S.	5.0	48
13	Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of <sup>131</sup> I?. <i>Nuclear Medicine Communications</i> , 2010, 31, 201-205.	1.1	45
14	Incidence of Postradioiodine Immunogenic Hyperthyroidism/Graves' Disease in Relation to a Temporary Increase in Thyrotropin Receptor Antibodies After Radioiodine Therapy for Autonomous Thyroid Disease. <i>Thyroid</i> , 2006, 16, 281-288.	4.5	42
15	Discovery of <sup>18</sup> F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions. <i>Journal of Nuclear Medicine</i> , 2019, 60, 817-823.	5.0	41
16	Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. <i>European Journal of Haematology</i> , 2005, 74, 348-352.	2.2	38
17	Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough?. <i>Nuclear Medicine Communications</i> , 2005, 26, 3-8.	1.1	37
18	Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in-vitro <sup>31</sup> P high-resolution NMR study. <i>NMR in Biomedicine</i> , 2000, 13, 8-13.	2.8	33

#	ARTICLE	IF	CITATIONS
19	FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma – An Updated Overview. <i>Cancers</i> , 2020, 12, 601.	3.7	33
20	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e398-e409.	4.6	28
21	Radioiodine therapy for thyroid volume reduction of large goitres. <i>Nuclear Medicine Communications</i> , 2009, 30, 466-471.	1.1	26
22	Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy. <i>Clinical Endocrinology</i> , 2012, 76, 297-303.	2.4	24
23	Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 66.	2.5	24
24	Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 46-53.	0.8	23
25	An <sup>18</sup> F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup> F-JK-PSMA-7 During the First Year of Application. <i>Journal of Nuclear Medicine</i> , 2020, 61, 202-209.	5.0	23
26	Economic evaluation studies in nuclear medicine: the need for standardization. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 663-680.	6.4	22
27	Iterative reconstruction: an improvement of technetium-99m MIBI SPET for the detection of parathyroid adenomas?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 485-489.	6.4	22
28	Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. <i>Clinical Cancer Research</i> , 2021, 27, 402-407.	7.0	20
29	An <sup>89</sup> Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 573-583.	5.0	17
30	Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases. <i>EJNMMI Physics</i> , 2018, 5, 32.	2.7	12
31	Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2022, 24, 115-125.	2.6	10
32	Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT. <i>PLoS ONE</i> , 2018, 13, e0209613.	2.5	9
33	Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2010, 49, 97-105.	0.7	8
34	[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2021, 23, 277-286.	2.6	8
35	FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in Hodgkin Lymphoma - Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG. <i>Blood</i> , 2007, 110, 212-212.	1.4	6
36	AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial. <i>Blood</i> , 2020, 136, 31-32.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Oligometastatic disease in biochemical recurrence of prostate cancer: Prevalence on PSMA PET/CT and consecutive metastasis-directed therapy – Experience at a tertiary referral center. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, 314-324.	0.7	3
38	Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3324-3325.	1.6	2
39	Avoidance of iodine deficiency/excess during pregnancy in Hashimoto’s thyroiditis. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 266-271.	0.7	2
40	Monitoring of Tumor Response to Neoadjuvant Radio-Chemotherapy of Esophageal Carcinoma by F-18-FDG-PET. <i>Chinese-German Journal of Clinical Oncology</i> , 2004, 3, 257-262.	0.1	0
41	Developments in oncological positron emission tomography/computed tomography assessment. <i>Journal of Thoracic Disease</i> , 2015, 7, E637-9.	1.4	0
42	Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, .	2.5	0